The change of some cytokine levels during immune-checkpoint inhibitor treatment in R/M head and neck cancer patients

被引：0
|
作者：
Komatsu, Nobukazu [1 ,2 ]
Ono, Takeharu [3 ]
Yokomizo, Kanako [2 ]
Yamada, Akira [2 ]
Umeno, Hirohito [3 ]
机构：
[1] Kurume Univ, Dept Immunol, Sch Med, Kurume, Japan
[2] Kurume Univ, Res Ctr Innovat Canc Therapy, Kurume, Japan
[3] Kurume Univ, Sch Med, Dept Otolaryngol, Kurume, Japan
来源：
CANCER SCIENCE | 2023年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-2201
引用
收藏
页码：1409 / 1409
页数：1
相关论文
共 50 条
  • [21] Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a "common language" for the new arena of cancer treatment
    Nishino, Mizuki
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
  • [22] Outcome of Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Post-Immune Checkpoint Inhibitor (ICI) Treatment
    Park, J. C.
    Merkin, R. D.
    Wirth, L.
    Patel, M. J.
    Roberts, T. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E41 - E41
  • [23] Good cops turn bad: The contribution of neutrophils to immune-checkpoint inhibitor treatment failures in cancer
    Zhang, Huajia
    Houghton, A. McGarry
    PHARMACOLOGY & THERAPEUTICS, 2021, 217
  • [24] Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment
    Sophia B. Strobel
    Devayani Machiraju
    Katharina A. Kälber
    Jessica C. Hassel
    Cancer Immunology, Immunotherapy, 2022, 71 : 2051 - 2056
  • [25] Bayesian Networks to Support Decision-Making for Immune-Checkpoint Blockade in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)
    Huehn, Marius
    Gaebel, Jan
    Oeser, Alexander
    Dietz, Andreas
    Neumuth, Thomas
    Wichmann, Gunnar
    Stoehr, Matthaeus
    CANCERS, 2021, 13 (23)
  • [26] Efficacy of nivolumab and ipilimumab in patients with hepatocellular carcinoma with prior immune-checkpoint inhibitor treatment.
    Cheon, Jaekyung
    Kang, Beodeul
    Jung, Sang-Hoon
    Kim, Chan
    Chon, Hongjae
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 554 - 554
  • [27] Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment
    Strobel, Sophia B.
    Machiraju, Devayani
    Kaelber, Katharina A.
    Hassel, Jessica C.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (08) : 2051 - 2056
  • [28] Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy in Patients With Cancer
    Huang, Xuan-zhang
    Gao, Peng
    Wang, Zhen-ning
    JAMA ONCOLOGY, 2020, 6 (04) : 586 - 587
  • [29] Impact of salvage chemotherapy after immune checkpoint inhibitor for recurrent or metastatic head and neck cancer
    Matoba, Takuma
    Minohara, Kiyoshi
    Kawakita, Daisuke
    Sawabe, Michi
    Takano, Gaku
    Oguri, Keisuke
    Murashima, Akihiro
    Iwaki, Sho
    Tsuge, Hiroshi
    Imaizumi, Sae
    Hojo, Wataru
    Kondo, Ayano
    Tsukamoto, Koji
    Iwasaki, Shinichi
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2024, 46 (08): : 1855 - 1864
  • [30] Immune-checkpoint inhibitors versus other systemic therapies in advanced head and neck cancer: a network meta-analysis
    Tang, Lingrong
    Liu, Tingting
    Chen, Jun
    Dang, Jun
    Li, Guang
    IMMUNOTHERAPY, 2021, 13 (06) : 541 - 555
12345